Your browser doesn't support javascript.
loading
Incidence, Risk, and Clinical Course of New-Onset Diabetes in Long COVID: Protocol for a Systematic Review and Meta-Analysis of Cohort Studies.
Talanki, Ananya Sri; Bajaj, Neha; Trehan, Twinkle; Thirunavukkarasu, Sathish.
Afiliação
  • Talanki AS; College of Arts and Sciences, Emory University, Atlanta, GA, United States.
  • Bajaj N; College of Arts and Sciences, Emory University, Atlanta, GA, United States.
  • Trehan T; Rollins School of Public Health, Emory University, Atlanta, GA, United States.
  • Thirunavukkarasu S; Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA, United States.
JMIR Res Protoc ; 13: e54853, 2024 Jun 04.
Article em En | MEDLINE | ID: mdl-38833277
ABSTRACT

BACKGROUND:

COVID-19, an infectious disease pandemic, affected millions of people globally, resulting in high morbidity and mortality. Causing further concern, significant proportions of COVID-19 survivors endure the lingering health effects of SARS-CoV-2, the pathogen that causes COVID-19. One of the diseases manifesting as a postacute sequela of COVID-19 (also known as "long COVID") is new-onset diabetes.

OBJECTIVE:

The aim of this study is to examine the incidence of new-onset diabetes in patients with long COVID and assess the excess risk compared with individuals who tested negative for COVID-19. The study also aims to estimate the population-attributable fraction for COVID-19 as a risk factor for new-onset diabetes in long COVID and investigate the clinical course of new-onset diabetes cases.

METHODS:

This is a protocol for a systematic review and meta-analysis. PubMed, MEDLINE, Embase, Scopus, and Web of Science databases will be systematically searched to identify articles published between December 2019 and July 2024. A comprehensive search strategy for each database will be developed using a combination of Medical Subject Headings terms, subject headings, and text words to identify eligible studies. Cohort studies and randomized controlled trials (only control arms) involving patients with COVID-19 of any age, with follow-up data on new-onset diabetes in long COVID, will be considered for inclusion. Controls will comprise individuals who tested negative for COVID-19, with or without other respiratory tract infections. Three independent reviewers (AST, NB, and TT) will perform article selection, data extraction, and quality assessment of the studies. A fourth reviewer (ST) will review the identified studies for final inclusion in the analysis. The random-effects DerSimonian-Laird models will be used to estimate the pooled incidence proportion (%), incidence rate of diabetes (per 1000 person-years), and risk ratio (with 95% CIs) for diabetes incidence.

RESULTS:

A total of 1972 articles were identified through the initial search conducted in August 2023. After excluding duplicates, conducting title and abstract screening, and completing full-text reviews, 41 articles were found to be eligible for inclusion. The search will be updated in July 2024. Currently, data extraction is underway, and the meta-analysis is expected to be completed in August 2024. Publication of the study findings is anticipated by the end of 2024.

CONCLUSIONS:

The study findings should provide valuable insights to inform both clinical practice and public health policies regarding the effective management of new-onset diabetes in patients with long COVID. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/54853.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Metanálise como Assunto / Diabetes Mellitus / Revisões Sistemáticas como Assunto / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Metanálise como Assunto / Diabetes Mellitus / Revisões Sistemáticas como Assunto / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article